694 related articles for article (PubMed ID: 30393621)
1. Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?
Dempke WCM; Fenchel K; Dale SP
Transl Lung Cancer Res; 2018 Sep; 7(Suppl 3):S275-S279. PubMed ID: 30393621
[TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
3. Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Krieger T; Pearson I; Bell J; Doherty J; Robbins P
Diagn Pathol; 2020 Jan; 15(1):6. PubMed ID: 32000815
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
5. The clinical utility of tumor mutational burden in non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Transl Lung Cancer Res; 2018 Dec; 7(6):639-646. PubMed ID: 30505708
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer.
Hu Z; Wang N; Zhang Y; Zhang D; Sun S; Yu H; Lin Y; Zhao X; Wang H; Wu X; Ichiki Y; Watanabe S; Gong Z; Chang J; Wang J
Transl Lung Cancer Res; 2024 Feb; 13(2):345-354. PubMed ID: 38496687
[TBL] [Abstract][Full Text] [Related]
7. The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers.
Takada K; Toyokawa G; Shoji F; Okamoto T; Maehara Y
Clin Lung Cancer; 2018 Mar; 19(2):120-129. PubMed ID: 29153898
[TBL] [Abstract][Full Text] [Related]
8. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Fehrenbacher L; Spira A; Ballinger M; Kowanetz M; Vansteenkiste J; Mazieres J; Park K; Smith D; Artal-Cortes A; Lewanski C; Braiteh F; Waterkamp D; He P; Zou W; Chen DS; Yi J; Sandler A; Rittmeyer A;
Lancet; 2016 Apr; 387(10030):1837-46. PubMed ID: 26970723
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review.
Brody R; Zhang Y; Ballas M; Siddiqui MK; Gupta P; Barker C; Midha A; Walker J
Lung Cancer; 2017 Oct; 112():200-215. PubMed ID: 29191596
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy.
Hendriks LE; Rouleau E; Besse B
Transl Lung Cancer Res; 2018 Dec; 7(6):647-660. PubMed ID: 30505709
[TBL] [Abstract][Full Text] [Related]
11. Current state of immunotherapy for non-small cell lung cancer.
Malhotra J; Jabbour SK; Aisner J
Transl Lung Cancer Res; 2017 Apr; 6(2):196-211. PubMed ID: 28529902
[TBL] [Abstract][Full Text] [Related]
12. Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?
Heeke S; Hofman P
Transl Lung Cancer Res; 2018 Dec; 7(6):631-638. PubMed ID: 30505707
[TBL] [Abstract][Full Text] [Related]
13. New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab.
Seetharamu N; Preeshagul IR; Sullivan KM
Lung Cancer (Auckl); 2017; 8():67-78. PubMed ID: 28761384
[TBL] [Abstract][Full Text] [Related]
14. Association of Tumor Mutational Burden With DNA Repair Mutations and Response to Anti-PD-1/PD-L1 Therapy in Non-Small-Cell Lung Cancer.
Chae YK; Davis AA; Raparia K; Agte S; Pan A; Mohindra N; Villaflor V; Giles F
Clin Lung Cancer; 2019 Mar; 20(2):88-96.e6. PubMed ID: 30425022
[TBL] [Abstract][Full Text] [Related]
15. A community challenge to predict clinical outcomes after immune checkpoint blockade in non-small cell lung cancer.
Mason M; Lapuente-Santana Ó; Halkola AS; Wang W; Mall R; Xiao X; Kaufman J; Fu J; Pfeil J; Banerjee J; Chung V; Chang H; Chasalow SD; Lin HY; Chai R; Yu T; Finotello F; Mirtti T; Mäyränpää MI; Bao J; Verschuren EW; Ahmed EI; Ceccarelli M; Miller LD; Monaco G; Hendrickx WRL; Sherif S; Yang L; Tang M; Gu SS; Zhang W; Zhang Y; Zeng Z; Das Sahu A; Liu Y; Yang W; Bedognetti D; Tang J; Eduati F; Laajala TD; Geese WJ; Guinney J; Szustakowski JD; Vincent BG; Carbone DP
J Transl Med; 2024 Feb; 22(1):190. PubMed ID: 38383458
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for PD-1/PD-L1 Blockade Therapy in Non-Small-cell Lung Cancer: Is PD-L1 Expression a Good Marker for Patient Selection?
Chae YK; Pan A; Davis AA; Raparia K; Mohindra NA; Matsangou M; Giles FJ
Clin Lung Cancer; 2016 Sep; 17(5):350-361. PubMed ID: 27137346
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer.
Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ
Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242
[TBL] [Abstract][Full Text] [Related]
18. Current views on tumor mutational burden in patients with non-small cell lung cancer treated by immune checkpoint inhibitors.
Berland L; Heeke S; Humbert O; Macocco A; Long-Mira E; Lassalle S; Lespinet-Fabre V; Lalvée S; Bordone O; Cohen C; Leroy S; Hofman V; Hofman P; Ilié M
J Thorac Dis; 2019 Jan; 11(Suppl 1):S71-S80. PubMed ID: 30775030
[TBL] [Abstract][Full Text] [Related]
19. Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
Herzberg B; Campo MJ; Gainor JF
Oncologist; 2017 Jan; 22(1):81-88. PubMed ID: 27534574
[TBL] [Abstract][Full Text] [Related]
20. A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients.
Takada K; Toyokawa G; Okamoto T; Shimokawa M; Kozuma Y; Matsubara T; Haratake N; Akamine T; Takamori S; Katsura M; Shoji F; Oda Y; Maehara Y
Clin Lung Cancer; 2017 Sep; 18(5):572-582.e1. PubMed ID: 28318951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
